http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2010041568-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416 |
| filingDate | 2009-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-WO2010041568-A1 |
| titleOfInvention | Indazole derivatives |
| abstract | A compound represented by the following general formula (A-1) and general formula (1) or a salt thereof is provided. Since the compound of the general formula (A-1) and the general formula (1) or a salt thereof has a β3 adrenergic receptor agonistic action, it is derived from diabetes, obesity, hyperlipidemia, depression, gallstones, increased biliary motility It is useful as a therapeutic and prophylactic agent for diseases, diseases resulting from hypergastrointestinal dysfunction, interstitial cystitis, overactive bladder or urinary incontinence, or a therapeutic and prophylactic agent for diseases associated with a decrease in tears. |
| priorityDate | 2008-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1138.